‘Prescriptions for Peace’ will highlight how dialogue, trust and societal wellbeing contribute to building resilient and peaceful societies.
CMI – Martti Ahtisaari Peace Foundation and Orion Corporation have launched a partnership that will bring insights from peace mediation to the wider public. Video interviews with CMI experts highlight how dialogue, trust and societal wellbeing contribute to building resilient and peaceful societies.
“We share CMI’s ambition for a more stable, just and healthy future for all, and see the core tenets of peacebuilding as an important part of our work and the broader societal discussion around health. We’re proud to start this partnership with them,” says Liisa Hurme, President and CEO of Orion Corporation.
Through the partnership, CMI’s peace mediation expertise will be shared by the partners to underline the practical skills that are needed for resolving conflicts and strengthening cooperation in societies. Specifically, the content will explain how dialogue, mediation and trust-building contribute to sustainable peace.
“Sustainable peace is about much more than just ending violence and getting to a deal. In mediation processes, we see how trust and dialogue gradually create the foundations for more stable societies. Through the Prescriptions for Peace series, we want to share some of these lessons from peace processes with a wider audience,” says Hanna Klinge, Deputy CEO of CMI.
The partnership aims to encourage broader public discussion about the foundations of sustainable peace and give weight to the importance of dialogue and cooperation in addressing complex societal challenges.
Orion Corporation
Orion Corporation is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.
